Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Search
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Sabine Reinig
For Sabine, who leads Boehringer Ingelheim's global people strategy, continuous development is the essence of a successful career. Read for more details!
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.